Titre : Politique publique

Politique publique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Polysomnography
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Politique publique : Questions médicales les plus fréquentes", "headline": "Politique publique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Politique publique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-16", "dateModified": "2025-03-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Politique publique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Politiques de régulation sociale", "url": "https://questionsmedicales.fr/mesh/D011049", "about": { "@type": "MedicalCondition", "name": "Politiques de régulation sociale", "code": { "@type": "MedicalCode", "code": "D011049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Politique de planification familiale", "alternateName": "Family Planning Policy", "url": "https://questionsmedicales.fr/mesh/D016656", "about": { "@type": "MedicalCondition", "name": "Politique de planification familiale", "code": { "@type": "MedicalCode", "code": "D016656", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.214" } } }, { "@type": "MedicalWebPage", "name": "Politique de santé", "alternateName": "Health Policy", "url": "https://questionsmedicales.fr/mesh/D006291", "about": { "@type": "MedicalCondition", "name": "Politique de santé", "code": { "@type": "MedicalCode", "code": "D006291", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Politique nutritionnelle", "alternateName": "Nutrition Policy", "url": "https://questionsmedicales.fr/mesh/D018673", "about": { "@type": "MedicalCondition", "name": "Politique nutritionnelle", "code": { "@type": "MedicalCode", "code": "D018673", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.650" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Apports nutritionnels recommandés", "alternateName": "Recommended Dietary Allowances", "url": "https://questionsmedicales.fr/mesh/D064167", "about": { "@type": "MedicalCondition", "name": "Apports nutritionnels recommandés", "code": { "@type": "MedicalCode", "code": "D064167", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.650.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Apports nutritionnels recommandés", "alternateName": "Recommended Dietary Allowances", "url": "https://questionsmedicales.fr/mesh/D064167", "about": { "@type": "MedicalCondition", "name": "Apports nutritionnels recommandés", "code": { "@type": "MedicalCode", "code": "D064167", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.650.500" } } }, { "@type": "MedicalWebPage", "name": "Contrôle du tabac", "alternateName": "Tobacco Control", "url": "https://questionsmedicales.fr/mesh/D000092843", "about": { "@type": "MedicalCondition", "name": "Contrôle du tabac", "code": { "@type": "MedicalCode", "code": "D000092843", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Politique anti-tabac", "alternateName": "Smoke-Free Policy", "url": "https://questionsmedicales.fr/mesh/D061845", "about": { "@type": "MedicalCondition", "name": "Politique anti-tabac", "code": { "@type": "MedicalCode", "code": "D061845", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.500" } } }, { "@type": "MedicalWebPage", "name": "Prévention du fait de fumer", "alternateName": "Smoking Prevention", "url": "https://questionsmedicales.fr/mesh/D000074606", "about": { "@type": "MedicalCondition", "name": "Prévention du fait de fumer", "code": { "@type": "MedicalCode", "code": "D000074606", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Politique anti-tabac", "alternateName": "Smoke-Free Policy", "url": "https://questionsmedicales.fr/mesh/D061845", "about": { "@type": "MedicalCondition", "name": "Politique anti-tabac", "code": { "@type": "MedicalCode", "code": "D061845", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.500" } } }, { "@type": "MedicalWebPage", "name": "Prévention du fait de fumer", "alternateName": "Smoking Prevention", "url": "https://questionsmedicales.fr/mesh/D000074606", "about": { "@type": "MedicalCondition", "name": "Prévention du fait de fumer", "code": { "@type": "MedicalCode", "code": "D000074606", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Politique publique", "alternateName": "Public Policy", "code": { "@type": "MedicalCode", "code": "D011640", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Krystyna Kongats", "url": "https://questionsmedicales.fr/author/Krystyna%20Kongats", "affiliation": { "@type": "Organization", "name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Jennifer Ann McGetrick", "url": "https://questionsmedicales.fr/author/Jennifer%20Ann%20McGetrick", "affiliation": { "@type": "Organization", "name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Kim D Raine", "url": "https://questionsmedicales.fr/author/Kim%20D%20Raine", "affiliation": { "@type": "Organization", "name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Sonja Grelle", "url": "https://questionsmedicales.fr/author/Sonja%20Grelle", "affiliation": { "@type": "Organization", "name": "Faculty of Psychology, Ruhr University Bochum." } }, { "@type": "Person", "name": "Wilhelm Hofmann", "url": "https://questionsmedicales.fr/author/Wilhelm%20Hofmann", "affiliation": { "@type": "Organization", "name": "Faculty of Psychology, Ruhr University Bochum." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Phenotypical Characterization of Obstructive Sleep Apnea in Premature Infants using Polysomnography.", "datePublished": "2023-08-29", "url": "https://questionsmedicales.fr/article/37642378", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/lary.30991" } }, { "@type": "ScholarlyArticle", "name": "Morphic Sensors for Respiratory Parameters Estimation: Validation against Overnight Polysomnography.", "datePublished": "2023-07-03", "url": "https://questionsmedicales.fr/article/37504102", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/bios13070703" } }, { "@type": "ScholarlyArticle", "name": "Beyond Polysomnography: Clinical Assessment of Pediatric Sleep Health and Sleep Problems.", "datePublished": "2023-03-21", "url": "https://questionsmedicales.fr/article/37120158", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jsmc.2023.02.001" } }, { "@type": "ScholarlyArticle", "name": "Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.", "datePublished": "2022-11-10", "url": "https://questionsmedicales.fr/article/36442421", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.sleep.2022.11.006" } }, { "@type": "ScholarlyArticle", "name": "Detecting atrial fibrillation in the polysomnography-derived electrocardiogram: a software validation study.", "datePublished": "2023-01-21", "url": "https://questionsmedicales.fr/article/36680625", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11325-023-02779-3" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Politique (principe)", "item": "https://questionsmedicales.fr/mesh/D057766" }, { "@type": "ListItem", "position": 4, "name": "Politiques de régulation sociale", "item": "https://questionsmedicales.fr/mesh/D011049" }, { "@type": "ListItem", "position": 5, "name": "Politique publique", "item": "https://questionsmedicales.fr/mesh/D011640" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Politique publique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Politique publique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Politique publique", "description": "Comment évaluer l'impact d'une politique publique en santé ?\nQuels outils sont utilisés pour le diagnostic des politiques ?\nQuelles sont les méthodes d'analyse des politiques publiques ?\nComment identifier les besoins de santé dans une communauté ?\nQuel rôle joue la recherche dans le diagnostic des politiques ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Polysomnography&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Politique publique", "description": "Quels symptômes indiquent un échec de la politique publique ?\nComment mesurer les symptômes de l'inefficacité des politiques ?\nQuels indicateurs de santé révèlent des problèmes systémiques ?\nComment les symptômes sociaux affectent-ils la santé publique ?\nQuels symptômes peuvent signaler un besoin de réforme ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Polysomnography&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Politique publique", "description": "Quelles stratégies de prévention sont efficaces en politique publique ?\nComment évaluer l'efficacité des programmes de prévention ?\nQuels obstacles à la prévention sont souvent rencontrés ?\nComment les politiques publiques peuvent-elles promouvoir la prévention ?\nQuel rôle joue l'éducation dans la prévention des maladies ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Polysomnography&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Politique publique", "description": "Comment les politiques influencent-elles les traitements disponibles ?\nQuels traitements sont souvent négligés par les politiques publiques ?\nComment évaluer l'efficacité des traitements en politique publique ?\nQuel est l'impact des politiques sur les traitements préventifs ?\nComment les politiques de santé affectent-elles les traitements psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Polysomnography&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Politique publique", "description": "Quelles complications peuvent résulter d'une mauvaise politique de santé ?\nComment les complications de santé sont-elles liées aux politiques publiques ?\nQuels sont les effets à long terme d'une politique de santé défaillante ?\nComment prévenir les complications liées aux politiques de santé ?\nQuel rôle jouent les données dans la prévention des complications ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Polysomnography&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Politique publique", "description": "Quels facteurs de risque sont souvent négligés par les politiques ?\nComment les politiques peuvent-elles réduire les facteurs de risque ?\nQuel impact a l'environnement sur les facteurs de risque ?\nComment les politiques de santé abordent-elles les facteurs de risque ?\nQuels sont les facteurs de risque liés aux comportements ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Polysomnography&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact d'une politique publique en santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact se mesure par des indicateurs de santé, des études d'impact et des analyses de données." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour le diagnostic des politiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des enquêtes, des analyses statistiques et des études de cas sont couramment utilisés." } }, { "@type": "Question", "name": "Quelles sont les méthodes d'analyse des politiques publiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent l'analyse qualitative, quantitative et l'analyse coût-bénéfice." } }, { "@type": "Question", "name": "Comment identifier les besoins de santé dans une communauté ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Par des enquêtes, des focus groups et l'analyse des données de santé existantes." } }, { "@type": "Question", "name": "Quel rôle joue la recherche dans le diagnostic des politiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La recherche fournit des données probantes pour orienter les décisions politiques et évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels symptômes indiquent un échec de la politique publique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des inégalités de santé croissantes et une augmentation des maladies évitables peuvent indiquer un échec." } }, { "@type": "Question", "name": "Comment mesurer les symptômes de l'inefficacité des politiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "En analysant les taux de morbidité, mortalité et l'accès aux soins de santé." } }, { "@type": "Question", "name": "Quels indicateurs de santé révèlent des problèmes systémiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les taux de vaccination, d'obésité et de maladies chroniques sont des indicateurs clés." } }, { "@type": "Question", "name": "Comment les symptômes sociaux affectent-ils la santé publique ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes comme la pauvreté et le chômage aggravent les conditions de santé et l'accès aux soins." } }, { "@type": "Question", "name": "Quels symptômes peuvent signaler un besoin de réforme ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une hausse des plaintes des citoyens et des résultats de santé dégradés peuvent signaler ce besoin." } }, { "@type": "Question", "name": "Quelles stratégies de prévention sont efficaces en politique publique ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les campagnes de sensibilisation, les programmes de vaccination et l'éducation à la santé." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des programmes de prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Par des études d'impact, des indicateurs de santé et des analyses de coûts." } }, { "@type": "Question", "name": "Quels obstacles à la prévention sont souvent rencontrés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le manque de financement, l'accès limité aux soins et la désinformation sont des obstacles majeurs." } }, { "@type": "Question", "name": "Comment les politiques publiques peuvent-elles promouvoir la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "En intégrant des programmes de prévention dans les systèmes de santé et en finançant des initiatives." } }, { "@type": "Question", "name": "Quel rôle joue l'éducation dans la prévention des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sensibilise la population aux comportements sains et aux risques de maladies." } }, { "@type": "Question", "name": "Comment les politiques influencent-elles les traitements disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les politiques déterminent le financement, l'accès et les protocoles de traitement en santé." } }, { "@type": "Question", "name": "Quels traitements sont souvent négligés par les politiques publiques ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements pour les maladies rares et les soins palliatifs sont souvent sous-financés." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des traitements en politique publique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Par des études cliniques, des revues systématiques et des analyses de coût-efficacité." } }, { "@type": "Question", "name": "Quel est l'impact des politiques sur les traitements préventifs ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les politiques favorisent l'accès aux vaccinations et dépistages, réduisant ainsi les maladies." } }, { "@type": "Question", "name": "Comment les politiques de santé affectent-elles les traitements psychologiques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elles influencent le financement et l'accès aux soins de santé mentale, souvent négligés." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une mauvaise politique de santé ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des inégalités de santé, une augmentation des maladies chroniques et un accès limité aux soins." } }, { "@type": "Question", "name": "Comment les complications de santé sont-elles liées aux politiques publiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des politiques inefficaces peuvent aggraver les conditions de santé et limiter l'accès aux traitements." } }, { "@type": "Question", "name": "Quels sont les effets à long terme d'une politique de santé défaillante ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une augmentation des coûts de santé, une détérioration de la santé publique et des inégalités croissantes." } }, { "@type": "Question", "name": "Comment prévenir les complications liées aux politiques de santé ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "En évaluant régulièrement les politiques et en adaptant les programmes aux besoins de la population." } }, { "@type": "Question", "name": "Quel rôle jouent les données dans la prévention des complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les données aident à identifier les problèmes, à évaluer les politiques et à orienter les interventions." } }, { "@type": "Question", "name": "Quels facteurs de risque sont souvent négligés par les politiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les déterminants sociaux de la santé, comme la pauvreté et l'éducation, sont souvent sous-estimés." } }, { "@type": "Question", "name": "Comment les politiques peuvent-elles réduire les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "En promouvant des environnements sains, l'éducation et l'accès aux soins préventifs." } }, { "@type": "Question", "name": "Quel impact a l'environnement sur les facteurs de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement pollué ou peu sûr augmente les risques de maladies et affecte la santé publique." } }, { "@type": "Question", "name": "Comment les politiques de santé abordent-elles les facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Elles intègrent des stratégies de prévention et d'éducation pour réduire les risques de maladies." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque liés aux comportements ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, l'alimentation malsaine et le manque d'activité physique sont des facteurs clés." } } ] } ] }

Sources (828 au total)

Phenotypical Characterization of Obstructive Sleep Apnea in Premature Infants using Polysomnography.

To use objective quantification of polysomnographic (PSG) parameters in premature infants to define the severity and nature of obstructions (partial hypopnea vs. total obstruction), along with the imp... Retrospective comparison of PSG features in 207 infants (<12 months) referred for sleep disordered breathing. Our study groups included term (> = 37 weeks GA, n = 162) and premature (<37 weeks GA, n =... Overall, premature infants had greater apnea severity (AHI premature 13.9/h vs. Term 7.9/h, p = 0.018). Additional analyses showed that the primary difference between premature and term infants is see... Children born premature have an OSA phenotype in infancy characterized by greater severity mostly due to frequent partial obstructions (hypopneas) rather than full obstructions (obstructive apnea). Pr... 3 Laryngoscope, 134:1933-1938, 2024....

Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.

Sleep disordered breathing (SDB) is common in patients with neuromuscular diseases, including spinal muscular atrophy (SMA). While polysomnography (PSG) findings have been described in natural history... We conducted a cross-sectional cohort study of children with SMA followed at the University of Florida Center for neuromuscular and rare diseases and had a diagnostic or split night PSG after SMA trea... Eight children were included in the cohort (four female), aged 5-250 days at diagnosis. Five children had two survival motor neuron 2 (SMN2) copies, two had three SMN2 copies and one subject had four ... SDB is common in treated children with SMA, regardless of age at diagnosis, treatment and neuromotor scores. While AHI may not be the only indicator of SDB in this population, indications, timing of P...

Detecting atrial fibrillation in the polysomnography-derived electrocardiogram: a software validation study.

The present study validated a software-based electrocardiogram (ECG) analysis tool for detection of atrial fibrillation (AF) and risk for AF using polysomnography (PSG)-derived ECG recordings.... The Stroke Risk Analysis® (SRA®) software was applied to 3-channel ECG tracings from diagnostic PSG performed in enrolled subjects including a subgroup of subjects with previously documented AF. No su... Of subjects enrolled in the study, 93 had previously documented AF and 178 of 186 had an ECG that could be analyzed by either method. In subjects with known history of AF, automated analysis using SRA... Sleep studies provide a valuable source of ECG recordings that can be easily subjected to software-based analysis in order to identify manifest AF and automatically assess the risk of PAF. For optimal...

[Analysis of Snoring in Patients with Obstructive Sleep Apnea (OSA) by Polysomnography and LEOSound].

Snoring was monitored in patients with obstructive sleep apnea (OSA) using the LEOSound-Monitor and simultaneously polysomnographic (PSG) recording. In obstructive apneas snoring is normally apparent ... In 40 patients with OSA (AHI > 15/h) simultaneous polysomnographic recordings were performed amongst long-term respiratory sound monitoring using the LEOSound monitor. Patients' average age was 57±11 ... 3778 obstructive apnea episodes were monitored. LEOSound identified snoring in 1921 (51,0%), polysomnography in 2229 (58,8%) obstructive apneas. Only in one patient there was a higher difference in sn... In nearly 60% of obstructive apnea events we found snoring during apnea-terminating hyperpnoea. LEOSound is a good diagnostic tool to monitor snoring. It is necessary to clarify why only 60% of all ob...

Risk of Developing Seizures in Children With Abnormal EEG Findings During Polysomnography.

Polysomnography (PSG) utilizes abbreviated electroencephalogram (EEG) to stage sleep. The aim of this study was to determine whether epileptiform abnormalities on this limited EEG coverage correlated ... A six-year retrospective chart review was performed assessing children with abnormalities on EEG during PSG. Children who underwent subsequent rEEG were included; children with a prior diagnosis of se... A total of 67 children met inclusion criteria. Average age was six years, and 43 (64%) were male. rEEG was normal in 16 (24%). Epileptiform abnormalities were focal in 36 (54%), generalized in eight (... Children with no history of seizures found to have abnormal EEG during PSG are likely to have an abnormal rEEG. Additionally, they have an increased risk for developing seizures....

Peripheral arterial tonometry versus polysomnography in suspected obstructive sleep apnoea.

Polysomnography (PSG) is the gold standard for the diagnosis of obstructive sleep apnoea (OSA). Home sleep apnoea testing with peripheral arterial tonometry (PAT) is a recommended diagnostic alternati... Retrospective monocentric cohort study. Patients with a PAT AHI ≥ 5/h followed by an in-hospital PSG within three months were included. All patients with a PAT AHI ≥ 5/h but a PSG AHI < 5/h were class... A total of 940 patients, 66% male with an average age of 55 ± 0.4 years and BMI of 31 ± 0.2 kg/m... Concordance between PAT and PSG diagnosis of sleep apnoea is good, particularly in moderate and severe OSA. Predictors for discordant results between PAT and PSG were age, sex and BMI. MACE risk is si...